BIOMAT Database Logo BIOMAT Database Logo

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. 1997

R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Texas Oncology, PA, Dallas, USA. rh.collins@baylordallas.edu

OBJECTIVE Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed may attain complete remissions when treated with transfusions of leukocytes obtained from the original bone marrow donor. We performed a retrospective study to characterize better this new treatment modality. METHODS We surveyed 25 North American BMT programs regarding their use of donor leukocyte infusions (DLI). Detailed forms were used to gather data regarding the original BMT, relapse, DLI, response to DLI, complications of DLI, and long-term follow-up evaluation. Reports of 140 patients were thus available for analysis. RESULTS Complete responses were observed in 60% (95% confidence interval [CI], 51.9% to 68.1%) of chronic myelogenous leukemia (CML) patients who received DLI and did not receive pre-DLI chemotherapy; response rates were higher in patients with cytogenetic and chronic-phase relapse (75.7%; 95% CI, 68.2% to 83.2%) than in patients with accelerated-phase (33.3%; 95% CI, 19.7% to 46.9%) or blastic-phase (16.7%; 95% CI, 1.9% to 31.9%) relapse. The actuarial probability of remaining in complete remission at 2 years was 89.6%. Complete remission rates in acute myelogenous leukemia (AML) (n = 39) and acute lymphocytic leukemia (ALL) (n = 11) patients who had not received pre-DLI chemotherapy were 15.4% (95% CI, 9.6% to 21.2%) and 18.2% (95% CI, 6.6% to 29.8%), respectively. Complete remissions were also observed in two of four assessable myeloma patients and two of five assessable myelodysplasia patients. Complications of DLI included acute graft-versus-host disease (GVHD) (60%; 95% CI, 51.4% to 68.6%), chronic GVHD (60.7%; 95% CI, 50.3% to 71.1%), and pancytopenia (18.6%; 95% CI, 12.2% to 25.0%). Pre-DLI characteristics predictive of complete response in CML patients were post-BMT chronic GVHD, pre-DLI disease status of chronic phase, and time interval between BMT to DLI less than 2 years. Acute and chronic GVHD post-DLI were highly correlated with disease response (P < .00001). CONCLUSIONS DLI results in complete remissions in a high percentage of patients with relapsed chronic-phase CML. Complete remissions are observed less frequently in patients with advanced CML and acute leukemia. GVHD and pancytopenia occur commonly; GVHD is highly correlated with response.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases

Related Publications

R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
March 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.
November 1997, Blood,
R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation.
March 1996, Bone marrow transplantation,
R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Adoptive immunotherapy using donor leukocyte infusions to treat relapsed hematologic malignancies after allogeneic bone marrow transplantation.
January 1999, Cancer treatment and research,
R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
[Donor leukocyte transfusion for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation].
April 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology,
R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation.
March 1992, Blood,
R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.
February 2000, Blood,
R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
September 1992, Bone marrow transplantation,
R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Donor leukocyte infusions for relapsed leukemia after allogeneic BMT.
October 1996, Hematology and cell therapy,
R H Collins, and O Shpilberg, and W R Drobyski, and D L Porter, and S Giralt, and R Champlin, and S A Goodman, and S N Wolff, and W Hu, and C Verfaillie, and A List, and W Dalton, and N Ognoskie, and A Chetrit, and J H Antin, and J Nemunaitis
Donor leukocyte infusion after allogeneic bone marrow transplantation was not effective for relapsed rhabdomyosarcoma.
April 1998, Bone marrow transplantation,
Copied contents to your clipboard!